SBBPのチャート
SBBPの企業情報
| symbol | SBBP |
|---|---|
| 会社名 | Strongbridge Biopharma plc （ストロングブリッジ・バイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 ストロングブリッジ・バイオファーマー(Strongbridge Biopharma plc)はグローバル商業段階のバイオ医薬品会社である。同社は各種疾患の治療法の開発・商品化に従事する。商業製品のKEVEYIS(ジクロロフェナミド)は原発性周期性麻痺の高カリウム血症、低カリウム血症および関連変種の治療に応用される。米国食品医薬品局（FDA）はKEVEYISの希少疾病用医薬品指定を認可している。同社は内分泌疾患治療用の臨床段階パイプラインを保有する。同社のリード化合物には、COR-003（レボケトコナゾール）、コルチゾール合成阻害剤、およびCOR-005（ベルドレイド）、ソマトスタチン類似体（SSA）が含まれる。同社は内在性クッシング症候群の治療のためにCOR-003を研究し、先端巨大症の治療のためにCOR-005を研究している。COR-003とCOR-005の両方は、FDAおよび欧州医薬品庁（EMA）から希少疾病用医薬品指定を受ける。 ストロングブリッジ・バイオファ―マはアイルランドのバイオ医薬品企業。主に稀有な疾患に焦点を当て、複数の相補型薬剤の開発とライセンス化に従事する。革新的な治療が求められる内分泌疾患の内因性クッシング症候群と先端巨大症に対する治療薬「COR-003」を、開発段階の薬剤候補に含む。本社はダブリン。米国ペンシルベニア州にも本社機能を持つ。 Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States. |
| 本社所在地 | 900 Northbrook Drive Suite 200 Trevose PA 19053 USA |
| 代表者氏名 | John H. Johnson ジョンH.ジョンソン |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 610-254-9200 |
| 設立年月日 | 42125 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 66人 |
| url | www.strongbridgebio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sbbp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -55.10100 |
| 終値（lastsale） | 4.89 |
| 時価総額（marketcap） | 228412134.72 |
| 時価総額 | 時価総額（百万ドル） 233.55020 |
| 売上高 | 売上高（百万ドル） 13.68300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 225.60820 |
| 当期純利益 | 当期純利益（百万ドル） -85.45400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Strongbridge Biopharma plc revenues increased from $1.5M to $8.2M. Net loss decreased 47% to $31.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease from $7.1M (expense) to $398.1M (income) Unrealized gain on fair value of warrant increase from $30.1M (expense) to $9.3M (income). |
SBBPのテクニカル分析
SBBPのニュース
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma 2021/10/05 20:05:00 Business Wire
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Xeris), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (Strongbridge). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdin
What Market views are telling to dormant Investors? Delta Air Lines, Inc. (NYSE:DAL 2.21%), Strongbridge Biopharma plc (NASDAQ:SBBP -1.88%) 2021/09/26 23:48:19 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post What Market views are telling to dormant Investors? Delta Air Lines, Inc. (NYSE:DAL 2.21%), Strongbridge Biopharma plc (NASDAQ:SBBP -1.88%) appeared first on Stocks Equity .
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc. 2021/09/23 20:01:00 Intrado Digital Media
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the Company or Strongbridge ) today announced that the High Court of Ireland (the Court ) has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. ( Xeris ) by means of scheme of arrangement (the Scheme ) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the Act ).
Dynamic volume-return relation of individual stocks: The Coca-Cola Company (NYSE:KO -1.64%), Strongbridge Biopharma plc (NASDAQ:SBBP 1.44%) 2021/09/20 00:10:28 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Dynamic volume-return relation of individual stocks: The Coca-Cola Company (NYSE:KO -1.64%), Strongbridge Biopharma plc (NASDAQ:SBBP 1.44%) appeared first on Stocks Equity .